The small molecule, which is widely used in cancer therapy, has been recently introduced into RDC (Radionuclide Drug Conjugate) development. The combination of molecular targeted therapy with radiotherapy is a creative concept to improve cancer therapy efficacy and reduce damage to healthy cells in patients.

Rdcthera offers a professional small molecule design and synthesis service with high quality for RDC development projects. More information: small molecules targeting